Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...124125126127128129130131132133134...10651066»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Postnatal corticosteroid usage in United Kingdom and Ireland neonatal units. (Pubmed Central) -  Sep 8, 2023   
    In terms of bone, methylprednisolone therefore is a safe treatment for Graves' orbitopathy. There is use of postnatal corticosteroids in all levels of neonatal care and much of the practice is not evidence based.
  • ||||||||||  Filspari (sparsentan) / Travere Therap, CSL Behring
    Review, Journal:  IgA nephropathy: a review of existing and emerging therapies. (Pubmed Central) -  Sep 8, 2023   
    A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.
  • ||||||||||  Journal:  Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. (Pubmed Central) -  Sep 8, 2023   
    Upfront autologous stem cell transplantation (ASCT) has been recommended for patients who are newly diagnosed with peripheral T-cell lymphoma (PTCL), and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), an anthracycline-based chemotherapy has been the frontline chemotherapy for PTCL...We conducted a randomized phase II study to compare CHOP with fractionated ifosfamide, carboplatin, etoposide, and dexamethasone (ICED) for patients eligible for ASCT...In summary, our study showed no therapeutic difference between CHOP and ICED in terms of response and PFS. Thus, CHOP might remain the reference regimen especially for AITL based on its better outcome in AITL, and upfront ASCT could be recommended as a consolidation of complete response in patients with PTCL.
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Trial termination, Trial primary completion date:  Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) -  Sep 8, 2023   
    P3,  N=12, Terminated, 
    The Oxulumis microcatheterization device performed as expected and was not associated with any complications. Active, not recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Oct 2022; No longer pursuing indication
  • ||||||||||  budesonide / Generic mfg., fluticasone / Generic mfg.
    Review, Journal:  Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review. (Pubmed Central) -  Sep 7, 2023   
    While more research evaluating the risk of ICS/INS for DM-related adverse events is needed, high doses of ICS/INS should be avoided when possible. The following strategies for ICS/INS dose minimization can be considered: Use of non-pharmacological measures (trigger avoidance, smoking cessation, vaccination to avoid infection), control of comorbid conditions, use of non-ICS-containing medications, inter-mittent rather than regular ICS dosing, and appropriate de-escalation of high ICS doses.
  • ||||||||||  olanzapine / Generic mfg.
    Journal:  Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial. (Pubmed Central) -  Sep 7, 2023   
    The incidence of postoperative nausea or vomiting in the first 24?h after surgery was lower in the olanzapine group (12/47, 26%) than in the control group (31/49, 63%) (p?=?0.008, RR 0.40 (95%CI 0.21-0.79)). Adding pre-operative oral olanzapine to intra-operative dexamethasone and ondansetron was highly effective in reducing the risk of postoperative nausea or vomiting in the first 24?hours after surgery in patients with a previous history of chemotherapy-induced nausea and vomiting and at least three Apfel risk factors for postoperative nausea or vomiting.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, IO biomarker:  Transcriptomics reveals apigenin alleviates airway inflammation and epithelial cell apoptosis in allergic asthma via MAPK pathway. (Pubmed Central) -  Sep 7, 2023   
    Our study began with oral gavage intervention using API (10, 20?mg/kg) or dexamethasone (DEX, 2?mg/kg) in a BALB/c mouse model of ovalbumin (OVA) sensitization...To further investigate the specific mechanism by which API acted, we established an in vitro model with house dust mite (HDM) stimulation, using API (10, 20??M) for administration intervention. The results showed that API was able to improve cell viability, inhibit ROS production, and reverse HDM-induced decreases in mitochondrial membrane potential (MMP) and apoptosis in airway epithelial cells via the MAPK pathway.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Journal:  Identification of biomarkers and sex differences in the placenta of fetal growth restriction. (Pubmed Central) -  Sep 7, 2023   
    Future longitudinal studies are needed to evaluate the impact of various management strategies on frailty. Our study provides an important theoretical and experimental basis to reevaluate the development of FGR from the placental standpoint and suggests a series of biomarkers for future clinical use.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Three cases of subcorneal pustular dermatosis with immunohistochemical examinations. (Pubmed Central) -  Sep 7, 2023   
    In case 2, a 70-year-old woman who had been treated for rheumatoid arthritis with adalimumab, salazosulfapyridine, and leflunomide developed 3- to 5-mm pustules on her trunk and thighs 4?days after flu vaccination...He was given oral prednisolone therapy, which was effective for the small pustules and some ulcers...Positive stainings for interleukin 8, interleukin 36?, and phospho-extracellular signal-regulated kinases 1 and 2 were observed in the upper layers of the epidermis below the pustules. Although the pathogenesis of subcorneal pustular dermatosis has not been clarified, the current results suggest that a variety of inflammatory cells, including those responsible for both innate and acquired immunity, are involved in the accumulation of neutrophils in subcorneal pustular dermatosis.
  • ||||||||||  fluticasone / Generic mfg.
    Journal:  Azelastine/fluticasone and allergic rhinitis in clinical practice. (Pubmed Central) -  Sep 7, 2023   
    Although the pathogenesis of subcorneal pustular dermatosis has not been clarified, the current results suggest that a variety of inflammatory cells, including those responsible for both innate and acquired immunity, are involved in the accumulation of neutrophils in subcorneal pustular dermatosis. No abstract available
  • ||||||||||  Omnaris (ciclesonide nasal spray) / Covis Pharma, Aerospan (flunisolide HFA) / Viatris, AbbVie, Xhance (fluticasone propionate intranasal spray) / OptiNose
    Journal:  The Rising Cost of Rhinologic Medications. (Pubmed Central) -  Sep 7, 2023   
    Her symptoms were prolonged and intractable until oral prednisolone was given. The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial primary completion date:  ISABEL: A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) (clinicaltrials.gov) -  Sep 7, 2023   
    P2,  N=50, Active, not recruiting, 
    The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations. Trial primary completion date: Aug 2023 --> Mar 2025
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial primary completion date:  Dexamethasone for Migraine - Dose Comparison (clinicaltrials.gov) -  Sep 7, 2023   
    P4,  N=209, Completed, 
    Trial primary completion date: Apr 2023 --> Apr 2024 Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg.
    Trial completion date:  Maintenance Therapy With Subcutaneous Bortezomib (clinicaltrials.gov) -  Sep 7, 2023   
    P2,  N=63, Active, not recruiting, 
    Trial completion date: May 2025 --> Oct 2027 | Trial primary completion date: May 2025 --> Oct 2027 Trial completion date: Nov 2022 --> Sep 2023
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion:  Transverse Abdominal Plane Block for Caesarean (clinicaltrials.gov) -  Sep 7, 2023   
    P=N/A,  N=100, Completed, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Completed